Companies House · 02543818

GILEAD SCIENCES LTD

UK registered company, private limited company, incorporated 27 Sept 1990.

Active

50
Public contracts: 4
Spend payments: £88.1k
Total spend

GILEAD SCIENCES LTD is a UK company registered at Companies House under number 02543818. This page links its registry record to its activity in UK public procurement — the contracts it has been awarded and the transparency-spend payments recorded against it.

Companies House record

Company number: 02543818
Status: Active
Company type: Private Limited Company
Incorporated: 27 Sept 1990
Country of origin: United Kingdom
Registered office: 280 HIGH HOLBORN, LONDON, WC1V 7EE
Nature of business (SIC): 46460 - Wholesale of pharmaceutical goods
Accounts category: FULL

View source on data.gov.uk

Public sector contracts

Contract awards linked to GILEAD SCIENCES LTD.

Procurement	Buyer	Awarded	Value
HIV Medicines	The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS National Framework for Transition products commencing 1 October 2024	NHS England	—	—
NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) for the treatment of HIV (Lot 1) 1 Nov 2024	NHS England	—	—
Antiretroviral Drugs	Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)	—	—
Amphotericin (Ambisome®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Amphotericin (Ambisome®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Hepatitis C Medicines	NHS National Services Scotland	—	—
Hepatitis C Medicines	NHS National Services Scotland	—	—
NP49119 Hepatitis C Medicines	NHS National Services Scotland	—	—
NP49119 Hepatitis C Medicines	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
NP49119 Hepatitis C Medicines	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
NP49119 Hepatitis C Medicines	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
NP49124 Hepatitis C Medicines	NHS Scotland	—	—
NP49124 Hepatitis C Medicines	NHS Scotland	—	—
NP49124 Hepatitis C Medicines	NHS Scotland	—	—
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and East	NHS England	—	—
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and East	NHS England	—	—
Invitation to offer for NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)	The NHS Commissioning Board (operating under the name of NHS England)	—	—
Anti-Retroviral Drugs	Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)	—	—
Proprietary Drugs	Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)	—	—
Emtricitabine / Rilpivirine / Tenofovir Disoproxil (Eviplera®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Emtricitabine / Tenofovir Alafenamide (Descovy®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Emtricitabine / Rilpivirine / Tenofovir Alafenamide (Odefsey®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil (Stribild®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Emtricitabine / Rilpivirine / Tenofovir Alafenamide (Odefsey®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Emtricitabine / Tenofovir Alafenamide (Descovy®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil (Stribild®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Emtricitabine / Rilpivirine / Tenofovir Disoproxil (Eviplera®)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	—	—
Contract for Remdesivir	Northern Health and Social Care Trust	—	—
Provision of CAR-T Cells	The Clatterbridge Cancer Centre NHS Foundation Trust	—	—
Provision of CAR-T Cells	The Clatterbridge Cancer Centre NHS Foundation Trust	—	—
REMDESIVIR	BELFAST HEALTH AND SOCIAL CARE TRUST	—	—
SOFOSBUVIR 400mg / VELPATASVIR 100mg Tablets 28 Tablet Pack	BELFAST HEALTH AND SOCIAL CARE TRUST	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives	NHS England	—	—
Remdesivir infusion	Southern Health and Social Care Trust	28 Apr 2026	£300k
Biktarvy	Southern Health and Social Care Trust	27 Apr 2026	£1.2m
NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024	NHS England	28 Oct 2024	£626.5m
NHS National Framework for Transition products commencing 1 October 2024	NHS England	29 Sept 2024	£16.2m
NHS London Branded Medicines - Tranche B - September 2023	NHS England	13 Jul 2023	£231.1m
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche	NHS England	13 Feb 2023	£480.4m
Supply of Remdesivir	Department of Health and Social Care (DHSC)	30 Mar 2022	£17.3m
Supply of Remdesivir	Department of Health and Social Care (DHSC)	28 Feb 2022	£5.7m
NHS Framework for the North of England, Branded Medicine	NHS England	7 Feb 2022	£238.9m
NHS Framework for the North of England, Branded Medicine	NHS England	7 Feb 2022	£238.9m

Supplier identities

How this company appears as a supplier across the data.

Recent transparency payments

4 payments recorded, totalling £88,081.

Payer	Description	Date	Amount
united-lincolnshire-hospitals-nhs-trust	PHARMACY	27 Mar 2014	£31.6k
salisbury-nhs-foundation-trust	DRUGS	11 Apr 2013	£21.3k
salisbury-nhs-foundation-trust	DRUGS	11 Apr 2013	£4.3k
united-lincolnshire-hospitals-nhs-trust	PHARMACY	10 Jan 2011	£30.8k

FAQs about GILEAD SCIENCES LTD

Is GILEAD SCIENCES LTD an active company?

GILEAD SCIENCES LTD (company number 02543818) is recorded as "Active", incorporated on 27 Sept 1990.

What does GILEAD SCIENCES LTD do?

Its Companies House nature-of-business (SIC) is: 46460 - Wholesale of pharmaceutical goods.

Has GILEAD SCIENCES LTD won UK public-sector contracts?

Yes — 50 public-sector contract awards are linked to this company in our data.

How much public money has GILEAD SCIENCES LTD received?

4 transparency-spend payments totalling £88,081 are recorded against GILEAD SCIENCES LTD.

Where is GILEAD SCIENCES LTD based?

Its registered office is 280 HIGH HOLBORN, LONDON, WC1V 7EE.

Understand any company's public-sector footprint

Enable links Companies House to live procurement and spend data — see contracts, buyers and payments for any UK supplier.

Get in touch with Enable